[go: up one dir, main page]

ATE209679T1 - Proteine mit faktor viii aktivität, verfahren zu deren herstellung unter verwendung von genetisch modifizierten zellen und diese enthaltende zusammensetzungen - Google Patents

Proteine mit faktor viii aktivität, verfahren zu deren herstellung unter verwendung von genetisch modifizierten zellen und diese enthaltende zusammensetzungen

Info

Publication number
ATE209679T1
ATE209679T1 AT95110468T AT95110468T ATE209679T1 AT E209679 T1 ATE209679 T1 AT E209679T1 AT 95110468 T AT95110468 T AT 95110468T AT 95110468 T AT95110468 T AT 95110468T AT E209679 T1 ATE209679 T1 AT E209679T1
Authority
AT
Austria
Prior art keywords
factor viii
proteins
production
compositions containing
genetically modified
Prior art date
Application number
AT95110468T
Other languages
English (en)
Inventor
Ooyen Albert Johannes Jose Van
Hans Pannekoek
Martinus P Verbeet
Leen Robert Willem Van
Original Assignee
Baxter Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Ag filed Critical Baxter Ag
Application granted granted Critical
Publication of ATE209679T1 publication Critical patent/ATE209679T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT95110468T 1987-06-12 1988-06-13 Proteine mit faktor viii aktivität, verfahren zu deren herstellung unter verwendung von genetisch modifizierten zellen und diese enthaltende zusammensetzungen ATE209679T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP87201121 1987-06-12

Publications (1)

Publication Number Publication Date
ATE209679T1 true ATE209679T1 (de) 2001-12-15

Family

ID=8197627

Family Applications (2)

Application Number Title Priority Date Filing Date
AT88201209T ATE142691T1 (de) 1987-06-12 1988-06-13 Proteine mit faktor-viii-aktivität, verfahren zu deren herstellung unter verwendung von genetisch modifizierten zellen und diese enthaltende pharmazeutische zusammensetzungen
AT95110468T ATE209679T1 (de) 1987-06-12 1988-06-13 Proteine mit faktor viii aktivität, verfahren zu deren herstellung unter verwendung von genetisch modifizierten zellen und diese enthaltende zusammensetzungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT88201209T ATE142691T1 (de) 1987-06-12 1988-06-13 Proteine mit faktor-viii-aktivität, verfahren zu deren herstellung unter verwendung von genetisch modifizierten zellen und diese enthaltende pharmazeutische zusammensetzungen

Country Status (19)

Country Link
US (2) US5171844A (de)
JP (1) JP2771827B2 (de)
KR (1) KR970002915B1 (de)
CN (1) CN1033760C (de)
AT (2) ATE142691T1 (de)
CA (1) CA1341208C (de)
DE (2) DE3856505T2 (de)
DK (1) DK172631B1 (de)
ES (2) ES2094111T3 (de)
FI (1) FI103731B1 (de)
GR (1) GR3021545T3 (de)
HU (2) HU213300B (de)
IE (1) IE69026B1 (de)
IL (1) IL86693A (de)
NO (1) NO301121B1 (de)
NZ (1) NZ224992A (de)
PT (1) PT87721B (de)
WO (1) WO1988009813A1 (de)
ZA (1) ZA884216B (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595886A (en) * 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
JPH0387173A (ja) * 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
FR2657884B1 (fr) * 1990-02-05 1994-09-02 Tm Innovation Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
ATE177472T1 (de) * 1990-09-14 1999-03-15 Chiron Corp Expression von makrophagen-induzierbaren proteinen (mips) in hefezellen
US20060122376A1 (en) * 1991-02-07 2006-06-08 Chiron Corporation Protein complexes having factor VIII:C activity and production thereof
US5859204A (en) * 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5888974A (en) * 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
AT403167B (de) * 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
US5641655A (en) * 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
AU5989796A (en) * 1995-06-06 1996-12-24 Board Of Regents Of The University Of Nebraska, by and on behalf of The University Of Nebraska Medical Center, The Organ function replacement compositions and methods of makin g and using the same
US7560107B2 (en) * 1996-06-26 2009-07-14 Emory University Modified factor VIII
JP2002517180A (ja) * 1997-12-05 2002-06-18 ジ・イミユーン・リスポンス・コーポレーシヨン 増大された発現を示す新規ベクターおよび遺伝子
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6200560B1 (en) * 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
EP1325681A1 (de) * 2001-12-11 2003-07-09 Société des Produits Nestlé S.A. Zusammensetzung für die Förderung des Knochenwachstums und die Erhaltung der Knochen
US7211558B2 (en) * 2002-05-22 2007-05-01 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of hemophilia A
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP2298926A1 (de) 2003-09-30 2011-03-23 The Trustees of The University of Pennsylvania Claden (Subtypen) und Sequenzen von Adeno-Assoziiertem Virus (AAV), diese enthaltende Vektoren und ihre Verwendungen
JP2008512097A (ja) 2004-09-07 2008-04-24 アーケミックス コーポレイション アプタマー医薬品化学
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
SG156618A1 (en) 2004-09-07 2009-11-26 Archemix Corp Aptamers to von willebrand factor and their use as thrombotic disease therapeutics
SI2363414T1 (sl) 2004-11-12 2022-09-30 Bayer Healthcare Llc Usmerjena modifikacija FVIII
EP2359867B1 (de) 2005-04-07 2014-10-08 The Trustees of The University of Pennsylvania Verfahren zur Erhöhung der Funktion eines AAV-Vektors
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
BR122019022434B8 (pt) * 2007-12-27 2021-07-27 Baxalta GmbH método para cultivar células de mamífero que secretam proteína heteróloga em um sobrenadante de cultura celular
AU2008347321B2 (en) * 2007-12-31 2015-05-21 Baxalta GmbH Transgenic non-human animals expressing human blood clotting factors
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
US20110072524A1 (en) * 2009-08-04 2011-03-24 Baxter International Inc. Transgenic Mouse Lacking Endogenous FVIII and VWF - A Model of Hemophilia A
WO2011028228A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
EP2506868B1 (de) 2009-12-06 2017-11-15 Bioverativ Therapeutics Inc. Chimäre und hybride faktor-viii-fc-polypeptide und verfahren zu ihrer anwendung
WO2011126808A2 (en) 2010-03-29 2011-10-13 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
HUE044419T2 (hu) 2010-07-09 2019-10-28 Bioverativ Therapeutics Inc Feldogozható egyetlen láncú molekulák és ezek alkalmazásával készült peptidek
WO2012006623A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Systems for factor viii processing and methods thereof
KR101956885B1 (ko) 2011-02-17 2019-03-12 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 조직 특이성 변경 및 ａａｖ９-매개 유전자 전달 개선을 위한 조성물 및 방법
EP2717898B1 (de) 2011-06-10 2018-12-19 Bioverativ Therapeutics Inc. Gerinnungsfördernde verbindungen und anwendungsverfahren dafür
KR102110736B1 (ko) 2011-07-08 2020-05-14 바이오버라티브 테라퓨틱스 인크. Viii 인자 키메라 및 하이브리드 폴리펩타이드, 그리고 이들의 사용 방법
EP2737311B1 (de) 2011-07-25 2020-12-02 Bioverativ Therapeutics Inc. Tests zur überwachung von blutungsstörungen
CA2850579A1 (en) 2011-10-18 2013-04-25 Carsten Horn Method for improving the stability of purified factor viii after reconstitution
CN104271150A (zh) 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 嵌合因子viii多肽及其用途
EP3453402B1 (de) 2012-01-12 2021-07-21 Bioverativ Therapeutics Inc. Reduzierung der immunogenität gegen den faktor viii bei patienten in einer faktor-viii-therapie
EP3564260B1 (de) 2012-02-15 2022-10-19 Bioverativ Therapeutics Inc. Faktor-viii-zusammensetzungen und verfahren zur herstellung und verwendung davon
EP2822577B1 (de) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Rekombinante faktor-viii-proteine
EP2858659B1 (de) 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Prokoagulationsverbindungen
JP2015525222A (ja) 2012-06-08 2015-09-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． キメラ性凝固因子
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
PT2882450T (pt) 2012-07-11 2020-02-19 Bioverativ Therapeutics Inc Complexo de fator viii com xten e a proteína fator de von willebrand, e utilizações do mesmo
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
CA2888806A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
EP3446700A1 (de) 2012-10-30 2019-02-27 Bioverativ Therapeutics Inc. Verfahren zur verwendung von fviii-polypeptid
HUE053136T2 (hu) 2013-02-15 2021-06-28 Bioverativ Therapeutics Inc Optimizált VIII. faktor gén
HUE047933T2 (hu) 2013-03-15 2020-05-28 Bioverativ Therapeutics Inc Faktor VIII polipeptid készítmények
CA2899089C (en) 2013-03-15 2021-10-26 Biogen Ma Inc. Factor ix polypeptide formulations
WO2015012924A2 (en) 2013-04-29 2015-01-29 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
EP4368194A3 (de) 2013-06-28 2024-07-31 Bioverativ Therapeutics Inc. Thrombinspaltbarer linker mit xten und dessen verwendungen
EP3043813B1 (de) 2013-08-08 2021-01-13 Bioverativ Therapeutics Inc. Reinigung von chimären fviii-molekülen
WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
EP4332839A3 (de) 2013-12-06 2024-06-05 Bioverativ Therapeutics Inc. Pharmakokinetische werkzeuge für populationen und verwendungen davon
EP4176894B1 (de) 2014-01-10 2024-02-28 Bioverativ Therapeutics Inc. Chimäre faktor-viii-proteine und ihre verwendungen
AU2015214245B2 (en) 2014-02-04 2020-09-10 Biogen Ma Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
CN105017410B (zh) * 2014-04-18 2018-06-08 北京诺思兰德生物技术股份有限公司 一种b区部分缺失型重组人凝血因子ⅷ
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
EP3626274B1 (de) 2015-04-16 2025-01-22 Emory University Rekombinante promotoren und vektoren zur proteinexpression in leber und verwendung davon
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
AU2016354550B2 (en) 2015-11-13 2020-04-16 Takeda Pharmaceutical Company Limited Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
SG11201804070XA (en) 2015-11-13 2018-06-28 Baxalta Inc Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
PL3411478T3 (pl) 2016-02-01 2022-10-03 Bioverativ Therapeutics Inc. Geny zoptymalizowanego czynnika VIII
EP3476937A4 (de) 2016-06-24 2019-12-04 Mogam Institute for Biomedical Research Chimäres protein mit fviii- und vwf-faktoren sowie verwendung davon
AU2017368328A1 (en) 2016-12-02 2019-07-18 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
IL266972B2 (en) 2016-12-02 2024-04-01 Bioverativ Therapeutics Inc Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors
AU2018313921B2 (en) 2017-08-09 2024-12-19 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
KR101952102B1 (ko) * 2017-12-07 2019-02-26 주식회사 지앤피바이오사이언스 단백질 발현량이 증대된 인자 ⅷ 변이체 발현벡터
CN111918674A (zh) 2018-02-01 2020-11-10 比奥维拉迪维治疗股份有限公司 表达因子viii的慢病毒载体的用途
BR112020020084A2 (pt) 2018-04-04 2021-01-05 Sigilon Therapeutics, Inc. Partícula, preparação de uma pluralidade de partículas, método de preparação de uma partícula, e, composição de partículas.
MX2020012397A (es) 2018-05-18 2021-04-12 Bioverativ Therapeutics Inc Metodos de tratamiento de la hemofilia a.
AU2019306194A1 (en) 2018-07-16 2021-02-04 Baxalta GmbH Gene therapy of hemophilia A using viral vectors encoding recombinant FVIII variants with increased expression
JP7602454B2 (ja) 2018-08-09 2024-12-18 バイオベラティブ セラピューティクス インコーポレイテッド 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
EP3736286A1 (de) 2019-05-09 2020-11-11 Biotest AG Einzelkettenfaktor-viii-molekül
CA3144630A1 (en) 2019-06-19 2020-12-24 Bioverativ Therapeutics Inc. Methods and compositions for treating hemophilia and low bone mineral density with factor viiifc protein
JP2023506171A (ja) 2019-12-12 2023-02-15 武田薬品工業株式会社 発現が上昇した組換えｆｖｉｉｉバリアントをコードするウイルスベクターを使用する、血友病ａの遺伝子療法
CA3183557A1 (en) 2020-06-24 2021-12-30 Bioverativ Therapeutics Inc. Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
JP2023537070A (ja) 2020-08-07 2023-08-30 アミカス セラピューティックス インコーポレイテッド 小胞を標的とするタンパク質及びその使用
US20240269241A1 (en) 2021-06-14 2024-08-15 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
IL310997A (en) 2021-08-23 2024-04-01 Bioverativ Therapeutics Inc Factor VIII gene optimization
EP4408874A1 (de) 2021-09-30 2024-08-07 Bioverativ Therapeutics Inc. Faktor viii polypeptid kodierende nukleinsäuren mit verminderter immunogenität
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2025008774A1 (en) 2023-07-05 2025-01-09 Takeda Pharmaceutical Company Limited Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657894A (en) 1983-03-31 1987-04-14 Scripps Clinic & Research Foundation New factor VIII coagulant polypeptides
US4886876A (en) 1983-03-31 1989-12-12 Scripps Clinic And Research Foundation Factor VIII coagulant polypeptides
US4857635A (en) 1983-03-31 1989-08-15 Scripps Clinic And Research Foundation Factor VIII coagulant polypeptides and monoclonal antibodies tof them
US5004804A (en) * 1984-01-12 1991-04-02 Nordisk Gentofte Method and composition for preparation of factor VIIIC
IL74909A (en) * 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
SE8501050D0 (sv) 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
DE3683980D1 (de) * 1985-04-12 1992-04-02 Genetics Inst Neue prokoagulierungsproteine.
US4769336A (en) 1985-05-24 1988-09-06 Scripps Clinic And Research Foundation Treatment of factor VIII inhibitors
KR910006424B1 (ko) * 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
FI98829C (fi) * 1986-01-27 1997-08-25 Chiron Corp Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
EP0251843A1 (de) 1986-06-06 1988-01-07 Transgene S.A. Verfahren zur Herstellung von Faktor VIII aus Säugerzellen
US5610278A (en) 1986-06-24 1997-03-11 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
NO872932L (no) * 1986-07-18 1988-01-19 Gist Brocades Nv Fremgangsmaate for fremstilling av proteiner med faktorviiiaktivitet ved hjelp av mikrobielle vertsceller, eksprimeringsvektorer, vertsceller, antibiotika.
IL84168A0 (en) * 1986-10-15 1988-03-31 Rorer Int Overseas Human factor viii-c analogs,process for the preparation thereof and pharmaceutical compositions containing the same
US4980456A (en) * 1987-04-06 1990-12-25 Scripps Clinic And Research Foundation Recombinant factor VIIIC derived fragments
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
JPH025890A (ja) 1988-06-24 1990-01-10 Chemo Sero Therapeut Res Inst ニワトリのβ−アクチンプロモーターを用いたヒトファクター８Ｃの製造方法
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning

Also Published As

Publication number Publication date
IL86693A0 (en) 1988-11-30
CN1033760C (zh) 1997-01-08
IL86693A (en) 1994-06-24
PT87721A (pt) 1988-07-01
DK58789A (da) 1989-02-09
CN1030609A (zh) 1989-01-25
US6316226B1 (en) 2001-11-13
NO890587L (no) 1989-02-10
NZ224992A (en) 1991-07-26
NO301121B1 (no) 1997-09-15
US5171844A (en) 1992-12-15
DE3855523T2 (de) 1997-02-06
CA1341208C (en) 2001-03-27
DK172631B1 (da) 1999-03-22
FI890643A0 (fi) 1989-02-10
DE3856505D1 (de) 2002-01-10
KR970002915B1 (ko) 1997-03-12
JP2771827B2 (ja) 1998-07-02
IE881755L (en) 1988-12-12
ATE142691T1 (de) 1996-09-15
HU211503A9 (en) 1995-11-28
NO890587D0 (no) 1989-02-10
DE3855523D1 (de) 1996-10-17
HU213300B (en) 1997-05-28
DE3856505T2 (de) 2002-08-08
ZA884216B (en) 1989-02-22
WO1988009813A1 (en) 1988-12-15
DK58789D0 (da) 1989-02-09
FI103731B (fi) 1999-08-31
FI890643L (fi) 1989-02-10
ES2094111T3 (es) 1997-01-16
ES2169095T3 (es) 2002-07-01
PT87721B (pt) 1992-10-30
FI103731B1 (fi) 1999-08-31
GR3021545T3 (en) 1997-02-28
JPH02500484A (ja) 1990-02-22
KR890701739A (ko) 1989-12-21
IE69026B1 (en) 1996-08-07

Similar Documents

Publication Publication Date Title
ATE209679T1 (de) Proteine mit faktor viii aktivität, verfahren zu deren herstellung unter verwendung von genetisch modifizierten zellen und diese enthaltende zusammensetzungen
DE68922216D1 (de) Zellenzuchtverfahren in bioreaktoren.
ATE110108T1 (de) Genetische modifizierung von endothelialen zellen.
ATE77104T1 (de) Menge und verfahren zur herstellung rekombinierter erzeugnisse in grosser ausbeute.
ES2147720T3 (es) Factor de celulas madre.
DE68914582D1 (de) Endothelin-DNA und ihre Verwendung.
ATE195148T1 (de) Prozess zur rekombinanten herstellung von hiv-2 - proteinen sowie zellen, die hiv-2 - proteine exprimiert
ATE69241T1 (de) Herstellung von polypeptiden mit humangammainterferon-aktivitaet.
HU895788D0 (en) Process for producing peptides and medical products containing them
DE68918279D1 (de) Plasminogenaktivator-varianten und verfahren zu ihrer herstellung.
EP0315118A3 (de) Endothelin kodierendes DNA und dessen Verwendung
ATE233321T1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
DE69116240D1 (de) Verfahren zur Herstellung von Zellprotein mit Anti-HIV-Wirkung
EP0211321A3 (de) Aminosäurezusammensetzung, Verfahren zu deren Herstellung und diese enthaltende medizinische Zusammensetzung
DE68912100D1 (de) 4,4,5,8-Tetramethyl-1-oxaspiro(2.5)octan, Verfahren zu seiner Herstellung und seine Verwendung als Ausgangsprodukt in der Herstellung von 2,2,3,6-Tetramethyl-cyclohexan-carboxaldehyd.
CS639089A3 (en) Micro-carriers with fibronectin suitable for cultivation of animal cells,process for preparing and use thereof
ATE29042T1 (de) Verfahren zum einbringen von dna in eukaryotischen zellen zur herstellung von proteinen.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee